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Abstract
Background: The epidemiological and molecular characteristics of hepatitis C virus (HCV) infection in the general
population have been poorly investigated in Africa. The aim of this study was to determine the prevalence, genotype
distribution and epidemic history of HCV in the Gabonese general population.
Methods/Principal Findings: A total of 4042 sera collected from adults in 220 villages in all nine administrative areas of the
country were screened for antibodies to HCV. HCV NS5B region sequencing was performed for molecular characterization
and population genetic analyses. Of 4042 tested sera, 455 (11.2%) were positive. The seroprevalence of HCV varied
significantly by administrative area, with the highest rate in Ogooue´-Lolo province (20.4%) and the lowest in Ogooue´-
Maritine province (3.7%). History of parenteral injections, past hospital admission and age over 55 years were independent
risk factors for HCV infection (p,0.0001). Phylogenetic analyses showed that 91.9% of the strains were genotype 4 (HCV-4),
5.7% genotype 1 and 2.2% genotype 2. HCV-4 strains were highly heterogeneous, with more than eight subtypes; subtype
4e predominated (57.3%). Coalescence analyses indicated that subtype 4e was the oldest, with an estimated most recent
common ancestor of 1702 [95% CI, 1418–1884]. The epidemic profile indicated that it spread exponentially during the first
part of the 20th century, probably by iatrogenic transmission.
Conclusions/Significance: These results confirm the endemicity of HCV subtype 4e in Gabon and show that its spread is
due to a cohort effect, with previous, possibly iatrogenic events. More extensive epidemiological studies are needed to
better characterize the route of transmission and the dissemination of HCV in Gabon.
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Introduction
Hepatitis C virus (HCV) is a leading cause of chronic liver
disease, cirrhosis, and hepatocellular carcinoma [1]. HCV infects
about 170 million people worldwide (3% of the world’s
population) and is recognized as a major public health problem
[2]. Like Egypt [3], Central Africa is considered a high-prevalence
region, antibodies against HCV being detected in more than 6%
of the population [4]. The highest prevalences in these countries
are typically observed in the oldest population groups [5–10].
HCV evolves very rapidly, resulting in high genetic diversity. It
is classified into six genotypes, each subdivided into multiple
subtypes [11]. Some subtypes are found only in particular regions,
while others are distributed globally. Genotype 1a is most
commonly detected in Europe and the USA, while genotype 1b
is distributed worldwide with high prevalences in Europe and the
USA as well as in Japan. Genotype 2 originated from West and
Central Africa and is common in Europe, Japan, and North
America. Genotype 3 is most common in India, Indonesia and
South-East Asia. Genotype 4 appears to be prevalent in Central
Africa and the Middle East, while genotype 5 is most frequently
reported in South Africa and genotype 6 in Hong Kong and
South-East Asia [12]. The time of divergence of HCV genotypes
circulating in those regions has been estimated: the age of the most
recent common ancestor (MRCA) of genotypes 1 and 4 in Central
Africa and of genotype 2 in West Africa was estimated to be 500–
600 years [13–16], whereas the age of the MRCA of genotype 6 in
East Asia was dated to 1100–1350 years [12], supporting the idea
of long-term endemic transmission of HCV in these regions.
Whereas circulation of most HCV subtypes remains restricted to
geographical regions with long-term endemic transmission of the
virus, a few HCV subtypes (1a, 1b, and 3a) are highly prevalent
‘epidemic’ strains that have spread outside the endemic regions
and are distributed globally [17]. It has been estimated that
epidemic subtypes 1a, 1b, and 3a emerged only about 100–150
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years ago and started to spread exponentially during the 20th
century [18–24]. Recent emergence and expansion is fully
consistent with the idea that worldwide dissemination of the
epidemic HCV subtypes is mainly due to the emergence of new,
efficient routes of viral transmission during the 20th century, such
as blood transfusion, hemodialysis, injection drug use, and non-
sterile medical injections [23,25,26].
In Gabon, the epidemiological picture is based on a few
population-based surveys conducted since 1993. A seroprevalence
of more than 6.5% was reported in Gabon [6,27], and the
available sequences indicated a predominance of genotype 4
[6,28]. The only study on the genetic diversity of HCV NS5B
sequences in Gabon showed that subtype 4e predominated in the
22 samples, and evolutionary analysis of the 4e sequences indicates
a period of increased transmission during the early 20th century
[6]. These population-based surveys have, however, been re-
stricted to small towns and are not representative of the general
population. As large-scale population-based studies are not
available in Gabon, the results cannot be used to estimate the
prevalence of HCV infection, the genotype distribution or the
burden of the disease in the general population.
We present here the results of a population-based study in all
nine provinces of Gabon. The purpose of the study was to
determine the seroprevalence of HCV in a stratified sample (by
age and geographical area) of the general rural population and to
establish the distribution of viral subtypes. The epidemic history of
HCV was deduced by analysis of independent sequences in the
NS5B region with new coalescence techniques [22].
Methods
Study Area and Population
Gabon is located in central Africa, transversed by the equator;
nearly 80% is covered by rain forest. The country has a surface
area of 267 667 km2 with about 1.5 million inhabitants (5.6
inhabitants/km2), 73% of whom live in urban areas. Administra-
tively, Gabon is divided into nine provinces with 2048 villages
located mainly along roads and rivers; few have more than 300
inhabitants. The main activities are subsistence farming, hunting,
gathering and fishing. This study was conducted on blood samples
collected between June 2005 and September 2008, during a project
on Ebola virus in Gabon [29]. Briefly, the survey covered 220
randomly selected villages in the nine administrative regions of
Gabon (range, 10–41 villages per province), most of which were
rural with fewer than 300 inhabitants. The multidisciplinary team
comprised a doctor from the Gabonese Ministry of Health, a nurse,
an epidemiologist, a virologist and laboratory technicians, who
made nine 1-month field missions to the study villages. All healthy
volunteers over 15 years old who had been residing in the village
for more than 1 year were eligible for the study.
The study protocol was reviewed and approved by the
Gabonese Ministry of Health (Research authorization
No. 00093/MSP/SG/SGAQM). The Health Director and the
Governor of each province received written information, as did
the traditional chief of each village. The planned studies were
described orally to all participants, and individual written consent
was obtained for blood sampling; parents’ written consent was
obtained for participating children and minors. People who gave
informed consent were interviewed on a structured epidemiolog-
ical questionnaire covering history of blood transfusion, jaundice,
mass treatment and mass vaccination, sharing toiletry items with
other family members, suspected nosocomial transmission (surgical
and dental procedures, hospitalizations) and suspected sporadic
transmission (ritual scarring, ritual circumcision for men, ritual
ear-piercing for women). A free medical examination and basic
medicines were provided to all participants and non-participants.
Blood smears for malaria diagnosis and field blood typing were
also proposed.
Blood samples were usually collected in the village health care
centers into 7-ml Vacutainer tubes containing EDTA (VWR
International, France). The tubes were transported to the field
laboratory for centrifugation (10 min, 20006g) daily. Plasma and
buffy coat were stored in aliquots at –20uC until the end of the
field mission and then transferred on dry ice to the Centre
International de Recherches Me´dicales de Franceville (CIRMF)
and kept at –80uC until analysis. Each plasma sample was
separated upon collection into two aliquots: one for serological
testing and the other for molecular characterization.
Serological Test
The presence of antibodies to HCV was checked with a third-
generation enzyme immunoassay (Monolisa anti-HCV plus
version 2, Biorad, Marnes-La-Coquette, France). The reactivity
of samples was determined as described previously [30]. Briefly,
a ratio was calculated for each sample by dividing its optical
density by the cut-off value. A sample was scored as positive if the
ratio was $6, whereas all samples with a ratio ,6 were scored as
negative.
HCV Genotyping and Subtyping
HCV genotyping and subtyping were performed by amplifica-
tion, sequencing and phylogenetic analysis of a 382-nt fragment of
the NS5B gene. Briefly, viral RNA was extracted from 140 ml of
plasma from HCV-positive individuals with a QIAamp Viral RNA
Mini Kit according to the manufacturer’s protocol (Qiagen,
Courtaboeuf, France). The portion of HCV NS5B gene from
extracted RNA was further amplified and sequenced as described
previously [31]. Briefly, RNA was subjected to hemi-nested
polymerase chain reaction (PCR) amplification, with Pr3 (59-
TATGAYACCCGCTGYTTTGCTC-39) and Pr4 (59-
GCNGARTAYCTVGTCATAGCCTC-39) as primers in the first
step and Pr3 and Pr5 (59-GCTAGTCATAGCCTCCGT-39) in
the second step. Combined reverse transcriptase (RT)-PCR was
carried out on 10 ml of extracted RNA (reaction mixture volume,
50 ml) with the one-step RT-PCR kit (Superscript III) and 200 nM
of each primer (Pr3, Pr4 and Pr5). The first step of RT-PCR with
Pr3 and Pr4 was carried out at 50uC for 30 min, then five cycles at
93uC for 30 s, 60uC for 45 s and 72uC for 1 min, followed
immediately by 35 cycles at 93uC for 30 s, 60uC with a drop of
20.3uC between each cycle and elongation at 72uC for 1 min.
The final elongation was at 72uC for 5 min. The second
amplification step with Pr3 and Pr5 was carried out on 2 ml of
the first PCR products at 95uC for 5 min, then 35 cycles at 95uC
for 30 s, 55uC for 30 s, 72uC for 30 s and a final elongation at
72uC for 10 min. The amplified NS5B 382-bp product was
analyzed by electrophoresis with a 2% agarose gel and ethidium
bromide staining. PCR products were purified on columns (Quick-
SpinTM Qiagen, Hilden, Germany) and sequenced. PCR primers
(Pr3 and Pr5) were used for sequencing both DNA strands. Cycle
sequencing was undertaken by the fluorescent dye terminator
technique (Big Dye Terminator Cycle sequencing; Applied
Biosystems, Courtaboeuf, France) with Ampli TaqTM DNA
polymerase according to the manufacturer’s instructions. Electro-
phoresis and data collection were done on an Applied Biosystems
ABI 3100 Genetic Analyzer. Sequence chromatograph files were
analyzed with sequence analysisTM and sequence navigatorTM
software.
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For phylogenetic analysis, NS5B nucleotide sequences were
aligned initially by CLUSTAL_X 1.81 [32] and subsequently
adjusted by hand. The sequences were compared with reference
sequences from the European HCV database (http://euhcvdb.
ibcp.fr/euHCVdb/) and the Los Alamos database (http://hcv.
lanl.gov/). Phylogenetic trees were estimated and assessed by the
bootstrapping and neighbor-joining methods under the Kimura
two-parameter substitution model, as implemented in MEGA
version 5.0 [33]. Bootstrapping was performed with 1000
replicates.
In order to confirm the results obtained by NS5B genotyping
and to identify probable recombinant HCV isolates, a 360-
nucleotide fragment of the core gene was amplified as described
previously [34] from a set of randomly selected samples. Briefly,
RNA was subjected to a nested PCR amplification with CoreOS
(59-ACTGCCTGATAGGGTGCTTGCGAG-39) and CoreOAS
(59-ATGTACCCCATGAGGTCGGC-39) as the primers in the
first step and CoreIS (59-AGGTCTCGTAGACCGTGCAT-
CATG-39) and CoreIAS (59-CAYGTRAGGGTATCGATGAC-
39) in the second step. cDNA synthesis was first was carried out on
10 ml of extracted RNA (reaction mixture volume, 20 ml) with the
RT kit (AMV-RT, Promega) and a random hexamer. The first
step of PCR with CoreOS and CoreOAS and the second PCR
with CoreIS and CoreIAS were carried out at 94uC for 3 min,
then two cycles at 95uC for 30 s, 60uC for 30 s, and 72uC for 30 s,
followed immediately by two of the same cycles with a drop of
21uC at each hybridation cycle until 51uC and then 20 cycles of
95uC for 30 s and 50uC for 30 s, with a final elongation at 72uC
for 7 min. The amplified core 360-bp product was analyzed by
electrophoresis on a 2% agarose gel with ethidium bromide
staining. The PCR products were purified and sequenced as
described above. The PCR primers CoreIS and CoreIAS were
used for sequencing both DNA strands.
Coalescent Analysis
The epidemic history of HCV subtypes 4e, 4f, 4c, 4t, and 4k,
the prevalences of which represent at least 5% of circulating
HCV isolates in Gabon, was investigated with a coalescent-based
strategy. Briefly, HCV demographic history was inferred by
Bayesian Monte Carlo Markov Chain (MCMC) analysis in
BEAST 1.4 software (http://.beast.bio.ed.ac.uk), as described
elsewhere [14]. We used an informative prior normal distribu-
tion, with a mean of 5.0610–4 and a standard deviation of 7.14
6 10–5. This distribution represents a best estimate of HCV
NS5B evolutionary rates, as obtained from two independent
prior analyses [22,24]. As recommended, a relaxed molecular
clock approach (uncorrelated lognormal model) was used,
thereby taking into account the variation in evolutionary rate
among lineages [35]. BEAST output files were analyzed with
TRACER 1.3 (http://tree.bio.ed.ac.uk/software/tracer/).
Statistical Analysis
Statistical analysis was performed with Epi-Info (version 6.04dfr,
ENSP-Epiconcept-InUS, 2001). The overall prevalence was
checked by the chi-squared test with Yates correction. p values
,0.05 were considered statistically significant. Data were then
analyzed by logistic regression. The continuous variable age was
categorized and entered into the model. The strength of the
association between age and HCV infection was estimated in the
multivariate analyses as odds ratios (ORs) with 95% confidence
intervals (CIs).
Nucleotide Sequence Accession Numbers
The nucleotide sequences obtained from the core and NS5B
gene of HCV were assigned GenBank accession numbers
JN642718–JN642776 (59 sequences) and JN642777–JN642987
(211 sequences), respectively.
Results
Study Population
We enrolled 4042 people in 220 randomly selected villages
covering all nine administrative areas of the country (Figure 1).
Blood samples and sociodemographic data were collected from all
participants. The mean age 6 SD of the study population was
47614.3 years (range, 15–90 years) (Table 1), and the sex
distribution was 2180 (53.9%) females and 1860 (46.1%) males.
There was no significant difference in mean age by province.
HCV Seroprevalence, Regional and Age Distribution and
Risk Factors for Infection
The seroprevalence of HCV in the study population was 11.2%
(95% CI, 10.3–12.3) (Table 2), with no significant difference
between females (11.0%; 95% CI, 9.7–12.4) and males (11.6%;
95% CI, 10.2–13.2).
The seroprevalence of HCV varied significantly according to
administrative area (Figure 1, Table 2). The seroprevalence in
Ogooue´-Lolo province (20.8%; 95% CI, 17.0–25.0) was signifi-
cantly higher than that in the other provinces (p,0.001), while
that in Ogooue´-Maritime province (3.7%; 95% CI, 1.5–7.6) was
significantly lower (p,0.001). Four patterns of seroprevalence
were found (Figure 1): ,5% (Ogooue´-Maritime), 5–10% (Moyen-
Ogooue´, Ogooue´-Ivindo and Woleu-Ntem), 11–15% (Estuaire,
Nyanga, Ngounie´, and Haut-Ogooue´), and .15% (Ogooue´-Lolo).
As shown in Table 2, the seroprevalence increased with age,
from 1.6% in the ,25-year age group to 12.4% at 46–55 years
and 20.5% at.55 years (chi squared test for trend, p,0.001). This
trend was similar in all geographical areas, with significant
increases with increasing age, the highest prevalence being in the
.55-year age group.
Univariate analysis of risk factors for HCV infection among
seropositive and seronegative people showed that the independent
predictors of positivity for HCV antibodies were a history of
parenteral injections (p,0.0001; OR, 1.86; 95% CI, 1.52–2.28),
past hospital admission (p,0.0001; OR, 1.42; 95% CI, 1.15–1.75)
and age .55 years (p,0.0001; OR, 3.77; 95% CI, 3.08–4.62)
(Table 3). The same analyses were done separately for each
administrative area, with similar results (data not shown, available
upon request).
HCV Genotype and Subtype Distribution
HCV RNA in the NS5B region could be amplified, sequenced
and analysed phylogenetically from 211 of the 455 HCV-
seropositive participants (46.4%). Figure 2 shows the estimated
phylogeny of these and previously published HCV NS5B
sequences. Of the 211 HCV samples, 194 (91.9%) were genotype
4 (HCV-4), 12 (5.7%) were genotype 1, and five (2.2%) were
genotype 2. Within genotype 4, more than half the sequences (121,
57.3%) were in one cluster, i.e. reference 4e subtype sequences; 21
(9.9%) were associated with 4c sequences, 21 (9.9%) with 4f, 11
(5.2%) with 4t, 10 (4.7%) with 4k, 4 (1.9%) with 4r, and 3 (1.4%)
with 4g. The remaining three (1.3%) sequences did not cluster
with current subtype HCV-4 sequences. Within genotype 1,
a cluster of five sequences (41.7%) corresponded to subtype 1e and
four (33.3%) to 1h. Two sequences were subtyped as 1l, and one
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was an unclassified HCV-1 subtype. The five HCV genotype 2
sequences formed a monophyletic cluster and were unclassified.
The genotype/subtype distribution of 211 HCV-RNA positive
samples according to geographical area is shown in Table 4.
Except in Woleu-Ntem province, subtype 4e was the most
prevalent. In some provinces, particularly those located in the
centre of the country, subtype 4e was found in more than 50% of
the typed samples. In the provinces in which subtype 4e
represented less than 50% of subtypes, a high level of co-
circulation (.20%) with other subtypes of genotype 4 was
observed. These provinces were principally those that border
other central African countries, i.e Woleu-Ntem and Estuaire
bordering Cameroon with subtype 4f and Haut-Ogooue´ bordering
the Republic of Congo with subtype 4c (Figure 1 and Table 4).
To validate the genotype/subtype assignment based on analysis
of the NS5B region, sequence analysis was performed on the core
region for 59 randomly selected isolates. The phylogenetic tree
(data not shown) confirmed the subtype assignment for all isolates.
Epidemic History of the Commonest Subtypes of HCV
Circulating in Gabon
In order to investigate the origin and spread of HCV-4 in this
population more carefully, subtypes with at least 10 NS5B
sequences (4e, 4f, 4c, 4t, and 4k) were selected, and the divergence
date and epidemic history were estimated with a Bayesian
coalescent approach.
Table 5 shows the date of the MRCA for the five most prevalent
Gabonese HCV-4 subtypes. Subtype 4e strain was the oldest, with
an estimated MRCA date of 1702 (95% CI, 1418–1884); the dates
of the 4f, 4c and 4t MRCAs were in the same range and were
estimated to be 1888 (95% CI, 1855–1915), 1881 (95% CI, 1813–
1930), and 1875 (95% CI, 1820–1918), respectively, while the 4k
MRCA appeared to be more recent (1944; 95% CI, 1922–1962).
The Bayesian skyline plot (Figure 3) depicts the estimated
change in the effective number of infected individuals over time,
from the HCV-4 MRCA to the year of sampling. Two patterns of
epidemic history were observed. The first was that of HCV 4e, 4f,
and 4c, the epidemic history of which was characterized by three
phases of population growth: an initial period of relatively constant
population size, a period of exponential growth during the first
part of the 20th century and, finally, slower exponential growth.
The second pattern was that of HCV 4t and 4k, which was
characterized by one phase of population growth, including
a period of exponential growth during the first part of the 20th
Figure 1. Map of Gabon with administrative regions, prevalence of antibodies to HCV and predominant subtypes.
doi:10.1371/journal.pone.0042002.g001
Table 1. Distribution and mean age of study population in
the nine administrative areas of Gabon.
Province Number of participants Mean age 6 SD (years)
Estuaire 314 46612.7
Haut Ogooue´ 363 45613.3
Moyen Ogooue´ 676 45614.7
Ngounie´ 303 48614.4
Nyanga 422 46612.0
Ogooue´ Ivindo 457 46614.6
Ogooue´ Lolo 423 52613.9
Ogooue´ Maritime 187 50618.7
Woleu Ntem 897 47614.6
Total 4042 47614.3
doi:10.1371/journal.pone.0042002.t001
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Table 2. Prevalence of hepatitis C virus infection according to age group and administrative area in Gabon.
Number of people with antibodies to HCV/number of people tested
(%; 95% confidence interval)
Age
(years) Estuaire
Haut
Ogooue´
Moyen
Ogooue´ Ngounie´ Nyanga O. Ivindo O. Lolo O. Maritime Woleu Ntem Total
#25 1/26 0/38 0/75 1/29 3/32 0/58 0/17 0/17 1/79 6/371
(3.8;
0.1–19.6)
(0.0;
0.0–9.3)
(0.0;
0.0–4.8)
(3.4;
0.09–17.8)
(9.4;
2.0–25.0)
(0.0;
0.0–9.3)
(0.0;
0.0–19.5)
(0.0;
0.0–19.5)
(1.3;
0.0–6.9)
(1.6;
0.6–3.5)
26–35 2/45 0/56 2/132 2/34 2/65 0/67 2/50 0/41 0/127 10/617
(4.4;
0.5–15.1)
(0.0;
0.0–6.3)
(1.5;
0.2–5.4)
(5.9;
0.7–19.7)
(3.1;
0.4–10.7)
(0.0;
0.0–5.4)
(4.0;
0.5–13.7)
(0.0;
0.0–8.6)
(0.0;
0.0–2.9)
(1.6;
0.8–3.0)
36–45 3/74 3/76 3/127 4/51 6/79 3/86 9/77 0/23 10/166 42/759
(4.1;
0.8–11.4)
(3.9;
0.8–11.1)
(2.4;
0.5–6.7)
(7.8;
2.2–18.9)
(7.6;
2.8–15.8)
(3.5;
0.7–9.9)
(11.7;
5.5–21.0)
(0.0;
0.0–14.8)
(6.0;
2.9–10.8)
(5.5;
4.0–7.4)
46–55 9/87 16/80 10/136 13/67 18/131 8/113 17/70 2/30 16/184 111/898
(10.3;
4.8–18.7)
(20.0;
11.9–30.4)
(7.4;
3.6–13.1)
(19.4;
10.8–30.9)
(13.7;
8.4–20.8)
(7.1;
3.1–13.5)
(24.3;
14.8–36.0)
(6.7;
0.8–22.1)
(8.7;
5.1–13.7)
(12.4;
10.3–14.7)
.55 25/82 28/113 23/206 22/122 31/115 29/133 60/209 5/78 63/341 286/1397
(30.5;
20.8–41.6)
(24.8;
17.1–33.8)
(11.2;
7.2–16.3)
(18.0;
11.7–26.0)
(27.0;
19.1–36.0)
(21.8;
15.1–29.8)
(28.7;
22.7–35.4)
(6.4;
2.1–14.3)
(18.5;
14.5–23.0)
(20.5;
18.4–22.7)
Total 40/314 48/363 38/676 44/303 60/422 40/457 88/423 7/187 90/897 455/4042
(12.7;
9.3–16.9)
(13.2;
9.9–17.1)
(5.6;
4.0–7.6)
(14.5;
10.8–19.0)
(14.2;
11.0–17.9)
(8.7;
6.3–11.7)
(20.8;
17.0–25.0)
(3.7;
1.5–7.6)
(10.0;
8.1–12.2)
(11.2;
10.3–12.3)
O, Ogooue´.
doi:10.1371/journal.pone.0042002.t002
Table 3. Univariate analysis of risk factors for HCV infection among HCV-positive and HCV-negative individuals.
Risk factor HCV positive, N (%) HCV negative, N (%) OR [95% CI]* p
Gender
Male 216 (11.6) 1644 (88.4) 1.00{ .0.05
Female 239 (11.0) 1941 (89.0) 0.94 [0.77; 1.14]
Age (years)
#55 169 (6.4) 2476 (93.6) 1.00{ ,0.001
.55 286 (20.5) 1111 (79.5) 3.77 [3.08; 4.62]
Blood or blood product transfusion
No 404 (11.4) 3138 (88.6) 1.00{ .0.05
Yes 41 (10.5) 351 (89.5) 0.91 [0.65; 1.28]
Past hospital admission
No 144 (9.3) 1402 (90.7) 1.00{ ,0.001
Yes 305 (12.7) 2091 (87.3) 1.42 [1.15; 1.75]
History of parenteral injections
No 270 (9.5) 2577 (90.5) 1.00{ ,0.001
Yes 180 (16.3) 923 (83.7) 1.86 [1.52; 2.28]
Jaundice
No 66 (7.8) 777 (92.2) 1.00{ .0.05
Yes 7 (11.5) 54 (88.5) 1.53 [0.67; 3.50]
Traditional scarification
No 230 (12.0) 1693 (88.0) 1.00{ .0.05
Yes 220 (10.9) 1805 (89.1) 0.90 [0.74; 1.10]
*OR, odds ratio; CI, confidential interval; {, reference.
doi:10.1371/journal.pone.0042002.t003
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century. The epidemic history of 4c precedes that of 4e and 4f by
several decades. While the 4c population increased exponentially
between 1950 and 1980, the 4e and 4f populations experienced
exponential growth between 1920 and 1960. In contrast, the 4t
and 4k populations did not reach growth equilibrium during this
period.
Discussion
We report here the largest HCV seroepidemiological study
performed in Gabon so far, with 4042 blood samples from all nine
provinces of the country. Overall, the seroprevalence of HCV was
11.2%, thus confirming a high prevalence of HCV infection in
Figure 2. Phylogram depicting the phylogenetic relations between partial (380-bp) HCV NS5B sequences obtained in this study
and representative sequences of HCV genotypes fromGenBank. The sequences from this study are shown in bold and grouped in their
corresponding clusters. Percentage bootstrap values (.70%) are shown at the respective nodes. All 211 sequences were submitted to GenBank with
the accession numbers JN642777–JN642987.
doi:10.1371/journal.pone.0042002.g002
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Gabon. Its heterogeneity (ranging from 3.7% to 20.8%) depended
on the area studied. Studies in other countries have also reported
significant intra-country variation in HCV prevalence [36–40].
The design of our study allowed investigation of HCV infection
according to sex and age; no statistically significant difference in
HCV distribution was found according to sex, as for community-
acquired hepatitis C in other regions of the world [41–43]. In our
study, a history of parenteral injections, past hospital admission,
and age .55 years were independent risk factors for HCV
infection. Similar findings were reported in neighbouring Camer-
oon [10], Central African Republic [9], and the Republic of
Congo [5]. These results confirm that the spread of HCV in
central Africa is due to a cohort effect, with previous, possibly
iatrogenic exposure. Iatrogenic events associated with massive and
generalized therapy and/or vaccination have recently been shown
to be a major cause of transmission of HCV in Egypt [3],
Cameroon [7,8], and the Central African Republic [9]. Such
procedures were repeated annually, often with non-sterile
equipment and serial arm-to-arm injections. The timing of these
events is consistent with the pattern of age-dependent seropreva-
lence. More extensive epidemiological studies are needed to better
characterize the route of transmission and dissemination of HCV
in Gabon.
This is the first large study of HCV molecular epidemiology in
Gabon. Our phylogenetic analysis indicates the circulation of three
HCV genotypes (1, 2 and 4), with a predominance of genotype 4.
In a previous study in Gabon, only HCV genotype 4 was found
[6,28]. The current study documents that there is high diversity in
genotypes 1 and 4 and many unsubtyped sequences. We [14,31]
and others [44] have reported the circulation of three HCV
genotypes (1, 2 and 4) in neighbouring Cameroon and Central
African Republic, with greater genetic diversity within genotype 4.
HCV genotype 4 also predominated and exhibited wide genetic
diversity in previous studies in Gabon [6], nearby Cameroon [31],
the Central African Republic [14] and the Republic of Congo [5].
An interesting finding is the difference in the predominant HCV-4
subtype in these four countries: subtype 4f in Cameroon [31],
subtype 4e in Gabon ([6] and this study), subtype 4k in the Central
African Republic [14] and 4c/4r in the Republic of Congo [5].
These five HCV-4 subtypes thus represent the signature HCV
infection in the corresponding country. Characterization of the full
genomes of these subtypes is needed for correct classification and
further studies.
Phylogenetic concordance was found in all 59 strains in which
both the NS5B and core regions were sequenced. Unlike in some
previous reports [45–52], genotype/subtype recombinant se-
quences or dual genotype/subtype infection were not observed
in this study, indicating that recombination is a rare event in
HCV, as reported previously [53,54].
The epidemic history of HCV-4e, -4f, -4c, -4t and -4r strains
was studied with a coalescent approach to population genetics.
The MRCA of subtype 4e in this study is older than that reported
by Ndong-Atome et al. [6] in a remote village of Gabon. This
suggests different epidemic histories of HCV-4e in Gabon, with
different periods of introduction according to the administrative
region. The MRCAs of subtypes 4f and 4c in this study are in the
same range as that of Cameroon [15] and the Republic of Congo
[5], suggesting a similar period of introduction. Interestingly, the
MRCA of subtype 4k in this study is more recent than that
reported by Njouom et al. [14] in a village in the Central African
Republic, suggesting that this subtype was introduced into Gabon
from that country. The similarities in the population histories of
Table 4. Distribution of hepatitis C virus genotypes and subtypes according to administrative area in Gabon.
Number of positive samples (% prevalence)
HCV
ge´notype
or subtype
Estuaire
(N =28)
Haut
Ogooue´
(N =27)
Moyen
Ogooue´
(N =29)
Ngounie´
(N =25)
Nyanga
(N =24)
Ogooue´
Ivindo
(N =25)
Ogooue´
Lolo
(N =24)
Woleu
Ntem
(N =24)
Ogooue´
Maritime
(N =5)
Total
(N =211)
4e 11 (39.3) 13 (48.1) 17 (56.6) 22 (88.0) 19 (79.2) 14 (56.0) 16 (66.7) 6 (25.0) 3 (60.0) 121 (57.3)
4c 1 (3.6) 9 (33.3) 1 (3.4) 0 1 (4.2) 4 (16.7) 5 (20.8) 0 0 21 (9.9)
4f 8 (28.6) 0 2 (6.9) 1 (4.0) 0 2 (8.0) 1 (4.2) 7 (29.2) 0 21 (9.9)
4t 2 (7.1) 0 2 (6.9) 0 0 1 (4.0) 1 (4.2) 5 (20.8) 0 11 (5.2))
4k 3 (10.7) 0 3 (10.3) 2 (8.0) 2 (8.3) 0 0 0 0 10 (4.7)
4r 1 (3.6) 2 (7.4) 0 0 0 0 1 (4.2) 0 0 4 (1.9)
4g 0 0 0 0 2 (8.3) 0 0 0 1 (20.0) 3 (1.4)
4un 0 2 (7.4) 0 0 0 1 (4.0) 0 0 0 3 (1.4)
1 2 (7.1) 0 2 (6.9) 0 0 1 (4.0) 0 6 (25.0) 1 (20.0) 12 (5.7)
2 0 1 (3.7) 2 (6.9) 0 0 2 (8.0) 0 0 0 5 (2.4)
N, number of samples tested.
doi:10.1371/journal.pone.0042002.t004
Table 5. Descriptive statistics from the empirical posterior
distribution of the date of the most recent common ancestors
(MRCAs) of Gabonese HCV NS5B partial sequences according
to HCV-4 subtype.
Subtype n Median date (years) 95% CI date (years)
4e 121 1702 1418–1884
4f 21 1888 1855–1915
4c 21 1881 1813–1930
4t 11 1875 1820–1918
4k 10 1944 1922–1962
These distributions were obtained by Bayesian inferences with BEAST software,
with a normal posterior distribution of the mean mutation rate at a mean of
56104 and a standard deviation of 7.146105. 95% credible confidence intervals
are delimited by the 0.025th and 0.975th quantiles.
doi:10.1371/journal.pone.0042002.t005
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Figure 3. Bayesian skyline plots estimated for HCV subtypes 4e, 4f, 4c, 4t, and 4k in Gabon. The middle line is the median estimate of
effective population size, and the envelope shows the 95% highest posterior density interval of this estimate.
doi:10.1371/journal.pone.0042002.g003
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HCV-4 in Gabon, Cameroon, the Central African Republic, and
the Republic of Congo, despite differences in the predominant
subtype, suggest that medical interventions amplified the HCV-4
subtype, which was introduced into cohorts of patients during
mass intravenous drug campaigns by mobile teams at health
centers or in villages. Less common subtypes presumably
correspond to those for which such amplification did not occur
or which occurred only at the end of the era of massive
administration of intravenous drugs, with fewer cycles of
amplification.
In conclusion, this study shows that, like neighbouring
Cameroon, the Central African Republic, and the Republic of
the Congo, Gabon has a high prevalence of HCV, especially
among older people, and, moreover, that it is highly heterogeneic
(ranging from 3.7% to 20.8%, depending on the area studied).
Fourteen subtypes, including nine subtype 4 strains, were
identified, suggesting that genotype 4, especially subtype 4e,
which predominates, has been endemic for a long time in Gabon.
Coalescence studies of subtypes 4e, 4f, and 4c with an epidemic
profile indicate that they spread exponentially during the first part
of the 20th century, probably due to iatrogenic transmission, as
reported in previous studies. In contrast, the 4t and 4k populations
did not reach growth equilibrium during this period and continue
to spread. Further studies are required to identity the risk factors
for transmission in the country.
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